GAIL SCHULZE - Corporate Board Profile

CERUS CORP

Filing Date	Source Excerpt
2010-04-23	Gail Schulze, 58, has served as a member of our Board since 2007. The Nominating and Corporate Governance Committee concluded that Ms. Schulze should continue to serve as a director of the Company in part due to her extensive experience in executive roles in both large and small life sciences organizations at various stages of development. She is currently the chairman and chief executive officer of Zosano Pharma, a private biopharmaceutical company. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table shows for the fiscal year ended December 31, 2009 certain information with respect to the compensation of all non-employee directors of the Company: ... Gail Schulze 48,000 28,483 0 0 76,483
2011-04-22	Gail Schulze, 59, has served as a member of our Board since 2007. The Compensation Committee of the Board comprises three (3) directors: Mr. Cassin (chair), Mr. Cozadd and Ms. Schulze, all of whom were on the Compensation Committee for all of 2010. Ms. Schulze became chair of the Compensation Committee in January 2011. The Nominating and Corporate Governance Committee comprises five (5) directors: Messrs. Cassin (Chair), Anderson, Cozadd, Rohn and Ms. Schulze, all of whom were on the Nominating and Corporate Governance Committee for all of 2010. For the year ended December 31, 2010, Gail Schulze received $34,000 in fees and $18,240 in option awards totaling $52,240.
2013-04-29	Gail Schulze, 61, has served as a member of our Board since 2007. The Nominating and Corporate Governance Committee concluded that Ms. Schulze continues to be a valuable member of the Board in part due to her extensive experience in executive roles in both large and small life sciences organizations at various stages of development. From May 2008 until June 2012, she was the Chief Executive Officer and Chairman of the Board of Directors of Zosano Pharma, a private biopharmaceutical company. ... The Compensation Committee is composed of three directors: Mr. Cassin, Mr. Cozadd and Ms. Schulze (Chair), all of whom were on the Compensation Committee for all of 2012. ... The Nominating and Corporate Governance Committee consists of five directors: Messrs. Cassin (Chair), Anderson, Cozadd, Swisher and Ms. Schulze, all of whom were on the Nominating and Corporate Governance Committee for all of 2012.
2014-04-30	Gail Schulze, 62, has served as a member of our Board since 2007. The Nominating and Corporate Governance Committee and the Board concluded that Ms. Schulze continues to be a valuable member of the Board in part due to her extensive experience in executive roles in both large and small life sciences organizations at various stages of development. From May 2008 until June 2012, she was the Chief Executive Officer and Chairman of the Board of Directors of Zosano Pharma, a private biopharmaceutical company. From May 2006 to March 2007, she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a global biopharmaceutical organization with three late-stage oncology programs. Prior to joining YM Biosciences in 2006, she was President, Chief Executive Officer and director of Eximias Pharmaceutical Corporation, also a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004, Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, a fully independent biologics subsidiary of Aventis, and from 1997 to 2001, she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997, she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995, Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards. She received a B.A. with highest honors in psychobiology from the University of California, Santa Cruz, studied neurophysiology at the University of Wisconsin and received her M.B.A. from the Stanford Graduate School of Business. The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2013 for each of the Board committees: Gail Schulze: Compensation Committee (Chair), Nominating and Corporate Governance Committee. The Compensation Committee reviews director compensation on a periodic basis. For the year ended December 31, 2013, the Amended Policy provides that each director, other than the Chair of the Board, who is not also one of our officers or employees, will be compensated for his or her services as a director at the rate of $35,000 per year. The Chair of the Board will receive an annual retainer of $57,500 per year. The annual retainer is paid to our non-employee directors in equal quarterly installments. In addition to the annual retainer, the chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committees will receive an additional annual retainer of $26,000, $12,500 and $10,000, respectively. Each other member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee who is not one of our employees will receive an annual retainer of $13,000, $8,000 and $6,000, respectively. Gail Schulze's total compensation for 2013 was $97,920.
2015-04-30	Gail Schulze, 63, has served as a member of our Board since 2007. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2014 for each of the Board committees: Gail Schulze Audit X, Compensation * (Chair). ... The following table shows for the fiscal year ended December 31, 2014 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2014. ... Gail Schulze Fees Earned or Paid in Cash($) 55,000 Option Awards($) 107,065 Total($) 162,065.
2016-04-29	Gail Schulze, 64, has served as a member of our Board since 2007. The Compensation Committee is currently composed of three directors: Mr. Cozadd, Ms. Schulze (Chair) and Dr. Witney.
2017-04-28	Gail Schulze, 65, has served as a member of our Board since 2007. ... The Compensation Committee is currently composed of three directors: Mr. Cozadd, Ms. Schulze (Chair) and Dr. Witney, all of whom were on the Compensation Committee for all of 2016. ... For the year ended December 31, 2016, each director, other than the Chair of the Board, who is not also one of our officers or employees, was compensated for his or her services as a director at the rate of $40,000 per year. ... Gail Schulze Fees Earned or Paid in Cash($) 55,000, Option Awards($) 61,611, Stock Awards($) 61,609, Total($) 178,220.
2018-04-27	Gail Schulze, 66, has served as a member of our Board since 2007. ... The Audit Committee is currently composed of three directors: Messrs. Anderson, and Swisher and Dr. Witney. ... The Compensation Committee is currently composed of two directors: Ms. Schulze (Chair) and Dr. Witney, both of whom were on the Compensation Committee for all of 2017. ... The Nominating and Corporate Governance Committee currently consists of three directors: Messrs. Anderson (Chair) and Swisher and Ms. Schulze. ... For the year ended December 31, 2017, each director, who is not also one of our officers or employees, other than the Chair of the Board, was compensated for his or her services as a director at the rate of $40,000 per year. ... Gail Schulze received total compensation of $147,610 in 2017.
2019-04-26	Gail Schulze, 67, has served as a member of our Board since 2007. From May 2008 until June 2012, she was the Chief Executive Officer and Chairman of the Board of Directors of Zosano Pharma, a biopharmaceutical company. From May 2006 to March 2007, she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a then global biopharmaceutical organization. Prior to joining YM Biosciences in 2006, she was President, Chief Executive Officer and director of Eximias Pharmaceutical Corporation, then a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004, Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, then a fully independent biologics subsidiary of Aventis, and from 1997 to 2001, she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997, she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995, Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards. She received a B.A. with highest honors in psychobiology from the University of California, Santa Cruz, studied neurophysiology at the University of Wisconsin and received her M.B.A. from the Stanford Graduate School of Business.
2020-04-24	Gail Schulze, 68, has served as a member of our Board since 2007. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table provides membership and meeting information for fiscal 2019 for each of the Board committees: Gail Schulze - Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee. ... The following table shows for the fiscal year ended December 31, 2019 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2019. Gail Schulze compensation: $168,434.
2021-04-23	Gail Schulze, 69, has served as a member of our Board since 2007... The Compensation Committee is currently composed of four directors: Ms. Schulze (Chair), Dr. Witney, and Messrs. Swisher and Moore... The Nominating and Corporate Governance Committee currently consists of three directors: Messrs. Anderson (Chair) and Swisher and Ms. Schulze... The following table shows for the fiscal year ended December 31, 2020 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2020... Gail Schulze Fees Earned or Paid in Cash($) 66,000, Option Awards($) 87,938, Stock Awards($) 84,262, Total($) 238,200.
2022-04-22	Gail Schulze, 70, has served as a member of our Board since 2007... The Compensation Committee is currently composed of three directors: Ms. Schulze (Chair), Dr. Witney, and Mr. Moore... The Nominating and Corporate Governance Committee currently consists of three directors: Mss. Nachtsheim (Chair) and Schulze, and Mr. Swisher... The following table shows for the fiscal year ended December 31, 2021 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2021... Gail Schulze: Fees Earned or Paid in Cash $66,000, Option Awards $83,674, Stock Awards $83,671, Total $233,344.
2023-04-28	Gail Schulze, 71, has served as a member of our Board since 2007. The Compensation Committee is currently composed of three directors: Ms. Schulze (Chair), Dr. Witney, and Mr. Moore, all of whom were on the Compensation Committee for all of 2022. The Nominating and Corporate Governance Committee currently consists of three directors: Mss. Nachtsheim (Chair) and Schulze, and Mr. Swisher.
2024-04-26	Gail Schulze, 72, has served as a member of our Board since 2007. ... Under our director compensation program in effect for 2023, each non-employee director was entitled to an annual grant of RSUs on the date of each of our annual meetings ... each of our non-employee directors other than Dr. Shan received an RSU grant covering 40,000 shares on the date of the 2023 Annual Meeting. ... The number of shares subject to the RSU awards was determined in 2023 by dividing the target dollar value ($200,000) by a price of $5.00 per share ... The aggregate grant date fair value of the annual RSU awards for 2023 granted on June 7, 2023, calculated in accordance with Topic 718 ... The total for Ms. Schulze is $167,600.